The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
Abstract
Widespread, increasing antibiotic resistance amongst the major respiratory pathogens has compromised traditional therapy of the major infective respiratory syndromes, including bacterial pneumonia and acute exacerbations of chronic bronchitis. Guidelines for antibiotic prescribing dating from the 1980s to 1990s, which attempted to address such problems, were commonly too prescriptive and difficult to apply, and took little account of end-user practice or locally prevalent resistance levels. Further confusion was caused by conflicting recommendations emanating from differing specialty groups. The evidence that such guidelines benefited either clinical outcomes or treatment costs has been disputed. They have probably had little effect on resistance emergence. We report the recommendations of an independent, multi-national, inter-disciplinary group, which met to identify principles underlying prescribing and guideline formulation in an age of increasing bacterial resistance. Unnecessary prescribing was recognized as the major factor in influencing resistance and costs. Antibiotic therapy must be limited to syndromes in which bacterial infection is the predominant cause and should attempt maximal reduction in bacterial load, with the ultimate aim of bacterial eradication. It should be appropriate in type and context of local resistance prevalence, and optimal in dosage for the pathogen(s) involved. Prescribing should be based on pharmacodynamic principles that predict efficacy, bacterial eradication and prevention of resistance emergence. Pharmacoeconomic analyses confirm that bacteriologically more effective antibiotics can reduce overall management costs, particularly with respect to consequential morbidity and hospital admission. Application of these principles should positively benefit therapeutic outcomes, resistance avoidance and management costs and will more accurately guide antibiotic choices by both individuals and formulary/guideline committees.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Don't Physicians Follow Clinical Practice Guidelines?: A Framework for Improvement
Cabana, M. D., Rand, C. S., Powe, N. R., Wu, A. W., Wilson, M. H., Abboud, P.-A. C., & Rubin, H. R. (1999) · JAMA · doi:10.1001/jama.282.15.1458 · Cited by 6,677
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection
Oliver, A., Cantón, R., Campo, P., Baquero, F., & Blázquez, J. (2000) · Science · doi:10.1126/science.288.5469.1251 · Cited by 1,465
Seppälä, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H., Lager, K., & Huovinen, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370701 · Cited by 1,206
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 1,000
Nichol, K. L., Margolis, K. L., Wuorenma, J., & Von Sternberg, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409223311206 · Cited by 996
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
The biological cost of antibiotic resistance
Andersson, D. I., & Levin, B. R. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00005-3 · Cited by 867
Community‐Acquired Pneumonia in Adults: Guidelines for Management
Bartlett, J. G., Breiman, R. F., Mandell, L. A., & File, Jr. (1998) · Clinical Infectious Diseases · doi:10.1086/513953 · Cited by 865
Trends in Antimicrobial Drug Prescribing Among Office-Based Physicians in the United States
McCaig, L. F. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520270048030 · Cited by 791
Austin, D. J., Kristinsson, K. G., & Anderson, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.1152 · Cited by 784
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia
Marrie, T. J. (2000) · JAMA · doi:10.1001/jama.283.6.749 · Cited by 731
Gonzales, R. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550110039033 · Cited by 717
Variation in antibiotic use in the European Union
Cars, O., Mölstad, S., & Melander, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04972-2 · Cited by 698
Self-citationRahal, J. J. (1998) · JAMA · doi:10.1001/jama.280.14.1233 · Cited by 642
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.2.223 · Cited by 589
Emergence of Drug-Resistant Pneumococcal Infections in the United States
Breiman, R. F. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510470035031 · Cited by 562
Guillemot, D., Carbon, C., Balkau, B., Geslin, P., Lecoeur, H., Vauzelle-Kervroëdan, F., Bouvenot, G., & Eschwége, E. (1998) · JAMA · doi:10.1001/jama.279.5.365 · Cited by 545
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Arason, V. A., Kristinsson, K. G., Sigurdsson, J. A., Stefansdottir, G., Molstad, S., & Gudmundsson, S. (1996) · BMJ · doi:10.1136/bmj.313.7054.387 · Cited by 492
Evaluating treatment protocols to prevent antibiotic resistance
Bonhoeffer, S., Lipsitch, M., & Levin, B. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12106 · Cited by 487
Enne, V. I., Livermore, D. M., Stephens, P., & Hall, L. M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04519-0 · Cited by 486
Macfarlane, J., Holmes, W., Macfarlane, R., & Britten, N. (1997) · BMJ · doi:10.1136/bmj.315.7117.1211 · Cited by 483
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435
Adaptation to the fitness costs of antibiotic resistance in Escherichia coli
Schrag, S. J., Perrot, V., & Levin, B. R. (1997) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.1997.0178 · Cited by 396
Pallares, R., Gudiol, F., Liñares, J., Ariza, J., Rufi, G., Murgui, L., Dorca, J., & Viladrich, P. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707023170104 · Cited by 373
Efficacy of Pneumococcal Vaccination in Adults: A Meta-analysis of Randomized Controlled Trials
Fine, M. J. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420230051007 · Cited by 370
Felmingham, D., & Grüneberg, R. N. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.191 · Cited by 368
File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R., Kojak, C., & Rubin, A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1965 · Cited by 360
Application of fluoroquinolone pharmacodynamics
Wright, D. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.669 · Cited by 342
The Population Genetics of Antibiotic Resistance
Levin, B. R., Lipsitch, M., Perrot, V., Schrag, S., Antia, R., Simonsen, L., Moore Walker, N., & Stewart, F. M. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.supplement_1.s9 · Cited by 314
Otitis Media—Principles of Judicious Use of Antimicrobial Agents
Dowell, S. F., Marcy, S. M., Phillips, W. R., Gerber, M. A., & Schwartz, B. (1998) · Pediatrics · doi:10.1542/peds.101.s1.165 · Cited by 293
Gwaltney, J. M., Scheld, W. M., Sande, M. A., & Sydnor, A. (1992) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(92)90169-3 · Cited by 264
Christenson, B., Lundbergh, P., Hedlund, J., & Örtqvist, Å. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04237-9 · Cited by 262
Worrall, G. J., Chaulk, P. C., & Freake, D. (1997) · Europe PMC (PubMed Central) · Cited by 252
Leach, A. J., Shelby-James, T. M., Mayo, M., Gratten, M., Laming, A. C., Currie, B. J., & Mathews, J. D. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.3.356 · Cited by 244
Ho, P.-L., Que, T.-L., Tsang, D. N.-C., Ng, T.-K., Chow, K.-H., & Seto, W.-H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1310 · Cited by 241
Breakthrough Pneumococcal Bacteremia in Patients Being Treated with Azithromycin and Clarithromycin
Kelley, M. A., Weber, D. J., Gilligan, P., & Cohen, M. S. (2000) · Clinical Infectious Diseases · doi:10.1086/318157 · Cited by 234
Marchant, C. D., Carlin, S. A., Johnson, C. E., & Shurin, P. A. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80601-8 · Cited by 229
Dagan, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.2.129 · Cited by 223
Gleason, P. P. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010046038 · Cited by 222
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J., Williams, R. R., Fowler, C. L., Cheung, W. K., & Chow, A. T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2256 · Cited by 217
Ho, P. L., Tse, W. S., Tsang, K. W. T., Kwok, T. K., Ng, T. K., Cheng, V. C. C., & Chan, R. M. T. (2001) · Clinical Infectious Diseases · doi:10.1086/319222 · Cited by 216
Prophylaxis and Treatment of Influenza
Oates, J. A., Wood, A. J. J., & Douglas, R. G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220706 · Cited by 209
Azithromycin: 3-Day Versus 5-Day Course in the Treatment of Respiratory Tract Infections in Children
Ficnar, B., Huzjak, N., Oreskovic, K., Matrapazovski, M., & Klinar, I. (1997) · Journal of Chemotherapy · doi:10.1179/joc.1997.9.1.38 · Cited by 202
Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8
Magee, J. T., Pritchard, E. L., Fitzgerald, K. A., Dunstan, F. D. J., & Howard, A. J. (1999) · BMJ · doi:10.1136/bmj.319.7219.1239 · Cited by 192
Wang, E. E. L., Einarson, T. R., Kellner, J. D., & Conly, J. M. (1999) · Clinical Infectious Diseases · doi:10.1086/520145 · Cited by 168
Jernigan, D. B. (1996) · JAMA · doi:10.1001/jama.1996.03530270046030 · Cited by 163
Antibiotic-Resistant Pneumococcal Disease in South African Children
Friedland, I. R., & Klugman, K. P. (1992) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1992.02160200042023 · Cited by 153
Grossman, R. F., Mukherjee, J., Vaughan, D., Eastwood, C., Cook, R. J., LaForge, J., & Lampron, N. (1998) · CHEST Journal · doi:10.1378/chest.113.1.131 · Cited by 146
Mechanisms of Quinolone Resistance
Hooper, D. C. (2014) · ASM Press eBooks · doi:10.1128/9781555817817.ch3 · Cited by 129
Baquero, F. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.suppl_a.117 · Cited by 123
A Nosocomial Outbreak of Fluoroquinolone‐ResistantStreptococcus pneumoniae
Weiss, K., Restieri, C., Gauthier, R., Laverdière, M., McGeer, A., Davidson, R., Kilburn, L., Bast, D. J., de Azavedo, J., & Low, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322658 · Cited by 115
Acute Exacerbations of Chronic Bronchitis
Ball, P. D., & Make, B. (1998) · CHEST Journal · doi:10.1378/chest.113.3_supplement.199s · Cited by 105
Self-citationReichmann, P., König, A. A., Liñares, J., Alcaide, F., Tenover, F. C., McDougal, L. K., Swidsinski, S., & Hakenbeck, R. (1997) · The Journal of Infectious Diseases · doi:10.1086/516532 · Cited by 99
Strategies to minimize the development of antibiotic resistance.
Baquero, F., & Negri, M. C. (1997) · PubMed · Cited by 95
Macrolide‐ResistantStreptococcus pneumoniaeand Use of Antimicrobial Agents
Pihlajamäki, M., Kotilainen, P., Kaurila, T., Klaukka, T., Palva, E., Huovinen, P., & the Finnish Study Group for Antimicrobial Resistance (FiRe‐Network) (2001) · Clinical Infectious Diseases · doi:10.1086/322735 · Cited by 94
Fatal Pneumococcal Pneumonia Attributed to Macrolide Resistanceand Azithromycin Monotherapy
WATERER, G. W., Wunderink, R. G., & Jones, C. B. (2000) · CHEST Journal · doi:10.1378/chest.118.6.1839-a · Cited by 93
Development of practice guidelines
Miller, J., & Petrie, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)90326-4 · Cited by 80
Highet, V. S., Forrest, A., Ballow, C. H., & Schentag, J. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.suppl_1.55 · Cited by 63
Therapy for pneumococcal infection at the millennium: doubts and certainties
Ball, P. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00104-7 · Cited by 57
Self-citationAUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval
Schentag, J. J., Nix, D. E., Forrest, A., & Adelman, M. H. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000920 · Cited by 48
Andes, D. R. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200104000-00010 · Cited by 47
Drugeon, H. B., Juvin, M. E., & Bryskier, A. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.suppl_3.55 · Cited by 46
Pharmacodynamics to combat resistance
Woodnutt, G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/oxfordjournals.jac.a020890 · Cited by 43
Clinical failures: the tip of the iceberg?
Garau, J. (2001) · Respiratory Medicine · doi:10.1016/s0954-6111(01)90022-8 · Cited by 41
Woodnutt, G., & Berry, V. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.35 · Cited by 40
Pressures on the general practitioner and decisions to prescribe
Weiss, M., Fitzpatrick, R. M., Scott, D., & Goldacre, M. (1996) · Family Practice · doi:10.1093/fampra/13.5.432 · Cited by 39
Performance failure of an evidence-based upper respiratory infection clinical guideline.
O’Connor, P. J., Amundson, G. H., & Christianson, J. (1999) · PubMed · Cited by 28
Thorburn, C. E., KNOTT, S. J., & Edwards, D. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.1973 · Cited by 24
Cited by
Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, M., & Müller, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15591-8 · Cited by 1,096
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Drug delivery strategies for poorly water-soluble drugs
Fahr, A., & Liu, X. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.403 · Cited by 568
Jacobs, M. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg321 · Cited by 467
Metadata
- Authors
- Ball, P.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 49
- Issue
- 1
- Pages
- 31-40
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2119192977
- Cited by
- 290
- References
- 75
- FWCI
- 29.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.